Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocedurenone - Novo Nordisk

Next Previous
X
Search
Drug Profile

Ocedurenone - Novo Nordisk

Alternative Names: KBP-5074; NN-6023

Latest Information Update: 02 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KBP Biosciences
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal hypertension

Most Recent Events

  • 26 Jun 2024 KBP Biosciences terminates the phase III Clarion-CKD trial in Renal hypertension in Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Croatia, Czechia, Georgia, Germany, Hong Kong, Hungary, Israel, South Korea, Latvia, Lithuania, Malaysia, Poland, Serbia, South Africa, Spain, Taiwan and the US due to not meeting its primary endpoint (NCT04968184)
  • 07 Mar 2024 Novo Nordisk plans a phase III trial for Heart failure and Renal hypertension (PO)
  • 16 Oct 2023 Novo Nordisk acquires ocedurenone from KBP Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top